'Advancing Bria-OTS as our second novel immunotherapy candidate into the clinic is a significant milestone for BriaCell. We believe personalization through our Bria-OTS immunotherapy platform will produce more potent and long-lasting responses than previously observed, with potential synergistic effects with the immune check point inhibitor,' stated Dr.
About Bria-OTS Platform
Awarded numerous US and international patents and supported by clinical data of Bria-IMT, BriaCell's lead clinical candidate - currently in a pivotal Phase 3 study for advanced metastatic breast cancer (ClinicalTrials.gov NCT06072612 ), Bria-OTS is BriaCell's personalized off-the-shelf immunotherapy platform, and the basis for BriaCell's '
An Investigational New Drug Application (IND) is currently open for the Bria-OTS breast cancer therapy also known as, Bria-BRES for advanced metastatic breast cancer. Bria-BRES will initiate a bucket trial (i.e. a study that investigates multiple product candidates in a single study) with other cancer indications.
Bria-OTS received a
About
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.
Safe Harbor
This press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about BriaCell's personalization through the Bria-OTS immunotherapy platform producing more potent and long-lasting responses than previously observed, with potential synergistic effects with the immune check point inhibitor; the preferred safety profile of Bria-OTS improving the quality of life and increasing the lifespan of heavily pretreated patients and Bria-BRES initiating a bucket trial with other cancer indications, are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading 'Risks and Uncertainties' in the Company's most recent Management's Discussion and Analysis, under the heading 'Risk Factors' in the Company's most recent Annual Information Form, and under 'Risks and Uncertainties' in the Company's other filings with the Canadian securities regulatory authorities and the
Contact:
Tel: 1-888-485-6340
Email: info@briacell.com
Email: julesa@coreir.com
(C) 2024 Electronic News Publishing, source